• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Company Reports
    • Presentations
    • Research
    • News & Media
  • Contact

The Sentiment

Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug

8 July 2022 News & MediaThe Sentiment

The cannabinoid based drug, licensed from Dolve Cann Global is the world’s first full-spectrum medicinal cannabis product (with less than 0.3% THC).

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1675268254anoit1675268254anret1675268254nihce1675268254torue1675268254n@ofn1675268254i1675268254

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2023 Neurotech International • Site by White Noise Communications

Download prospectus